Lyell Immunopharma Inc.
LYEL | NASDAQ
$11.15
+$0.22 (+2.01%)
Sep 22, 2026, 12:13 PM ET · Market open
Market Data
Market Cap $267.83M
Enterprise Value $100.66M
Beta -0.07
Average Volume 152.67K
Shares Outstanding (Diluted) 23.36M
Shares Change YoY 57.94%
Institutional Ownership 54.74%
Exchange NASDAQ
ISIN US55083R2031
Price Performance
Price Change 1M -30.0%
Price Change 3M -13.5%
Price Change 6M -45.7%
Price Change YTD -62.3%
Price Change 1Y -17.0%
Price Change 3Y -62.6%
Price Change 5Y -95.5%
1M CAGR (ann.) -25.7%
1Y CAGR (ann.) -13.5%
5Y CAGR (ann.) -49.1%
All-Time CAGR -47.9%
Valuation
PE Ratio -0.93
Forward PE N/A
PEG Ratio 0.01
Forward PEG -0.14
PS Ratio 9,919.73
Forward PS 23,731.40
PB Ratio 1.15
P/FCF Ratio -1.55
P/Adj. FCF Ratio -1.26
P/OCF Ratio -1.92
EV/Sales 3,728.32
EV/EBIT -0.49
EV/EBITDA -0.51
EV/FCF -0.58
Earnings Yield -107.7%
FCF Yield -64.4%
Adj. FCF Yield -79.2%
Financial Health
Net Cash $167.17M
Total Debt $36.93M
Cash & Short-Term Investments $204.1M
Total Assets $311.15M
Current Ratio 5.36
Quick Ratio 5.36
Debt / Equity Ratio 0.16
Debt / EBITDA -0.19
Debt / FCF -0.21
OCF / Debt -4.65
Interest Coverage 0.00
Altman Z-Score -7.01
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin -8537.0%
Operating Profit Margin -542522.2%
EBITDA Margin -885037.0%
Net Profit Margin -920285.2%
FCF Margin -639148.2%
Adj. FCF Margin -785918.5%
SBC / Revenue 130863.0%
SBC Impact (per share) -23.0%
Returns
Return on Assets -79.9%
Return on Equity -91.6%
Return on Invested Capital -70.8%
Return on Capital Employed -70.8%
Return on Tangible Assets -79.9%
Historical Growth (CAGR)
Revenue CAGR 3Y -91.8%
Revenue CAGR 5Y -68.3%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -99.1%
EPS CAGR 5Y -67.2%
EPS CAGR 10Y N/A
FCF CAGR 3Y -4.0%
FCF CAGR 5Y 2.0%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 7
EPS Growth Next 3Y 23.8%
Revenue Growth Next 3Y 1740.5%
Earnings Date Nov 9, 2026
EPS Estimate (next Q) -$2.06
EPS Growth Est (next Q) -3.3%
Revenue Est (next Q) $3.83K
Revenue Growth Est (next Q) -74.5%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $42.67
Price Target Upside 290.4%
Cash Flow
Operating Cash Flow $-171.77M
Free Cash Flow $-172.57M
Adj. Free Cash Flow $-212.2M
FCF Per Share -$5.73
OCF Per Share -$5.70
OCF/S Ratio -493555.6%
Income Statement
Revenue $27K
Gross Profit $-2.31M
Operating Income $-146.48M
EBITDA $-198.19M
Net Income $-248.48M
EPS (Diluted) -$11.77
Revenue / Employee $167.70
Profit / Employee $-1.54M
Employees 161
Add to Watchlist
Select watchlists to add or remove LYEL